Blog
RSS FeedPosted by Michael Wonder on 22 Oct 2020
FDA approves first treatment for COVID-19
22 October 2020 - Today, the U.S. Food and Drug Administration approved the antiviral drug Veklury (remdesivir) for use in adult ...
Posted by Michael Wonder on 22 Oct 2020
Nexplanon recommended after second submission
22 October 2020 - The first submission was withdrawn. ...
Posted by Michael Wonder on 22 Oct 2020
Will HIRA resume talk to grant benefits for anti-diabetic combo drugs?
22 October 2020 - Three makers of SGLT-2 inhibiting anti-diabetic drugs said they would seek changes in approval conditions to ...
Posted by Michael Wonder on 22 Oct 2020
CADTH in favour of new indication for Soliris
22 October 2020 - CADTH has finalised its assessment of eculizumab for adult patients with refractory generalised myasthenia gravis. ...
Posted by Michael Wonder on 22 Oct 2020
Trump promised seniors drug discount cards. They may be illegal.
22 October 2020 - A proposal announced by President Trump last month was to send older Americans $200 discount cards to ...
Posted by Michael Wonder on 22 Oct 2020
Remdesivir’s hefty price tag ignores NIH investment in its creation
22 October 2020 - Throughout the Democratic presidential primary, candidates cast a spotlight on the broken U.S. health care system ...
Posted by Michael Wonder on 22 Oct 2020
Budget is why PHARMAC is letting down New Zealanders, CEO says
22 October 2020 - PHARMAC is struggling to cater to the demand of Kiwis. ...
Posted by Michael Wonder on 22 Oct 2020
PHARMAC decision pending on life-changing diabetes medications
22 October 2020 - Government drug-funding agency PHARMAC is expected to decide next week whether it will fund two new ...
Posted by Michael Wonder on 22 Oct 2020
Leo Pharma announces U.S. FDA approval for Enstilar (calcipotriene and betamethasone dipropionate) foam U.S. Prescribing Information update to include data in long-term use in plaque psoriasis treatment
22 October 2020 - U.S. Prescribing Information updated to include PSO-LONG clinical trial data concerning long-term use (52 weeks) of twice-weekly ...
Posted by Michael Wonder on 22 Oct 2020
F2G receives second US FDA breakthrough therapy designation for Olorofim
22 October 2020 - In Phase 2b development for the treatment of life-threatening fungal infections. ...
Posted by Michael Wonder on 22 Oct 2020
Patients, health organisations band together to bring breakthrough treatments to Canada sooner
21 October 2020 - Thirteen health charities and patient groups are calling on the Canadian government to improve access to ...
Posted by Michael Wonder on 22 Oct 2020
$10,000 on new drugs every four months keeps melanoma patient alive
21 October 2020 - Graham Venning was given “weeks perhaps months” to live at the start of the year but ...
Posted by Michael Wonder on 21 Oct 2020
Priority review granted to Ascentage Pharma's new drug application for olverembatinib (HQP1351), the first third generation BCR-ABL inhibitor in China
21 October 2020 - Ascentage Pharma today announced that the Center for Drug Evaluation of China's National Medical Products Administration has ...
Posted by Michael Wonder on 21 Oct 2020
U.S. FDA grants fast track designation for ASP0367/MA-0211, a selective PPARδ modulator being developed for the treatment of primary mitochondrial myopathies
20 October 2020 - Astellas Pharma today announced that the U.S. FDA has granted fast track designation for the development ...
Posted by Michael Wonder on 21 Oct 2020
A prescription for America’s drug pricing problem?
21 October 2020 - Sky-high prescription drug costs remains one of the most hotly contested issues in healthcare today. ...